Abstract
Leptomeningeal carcinomatosis (LMC) secondary to metastatic breast cancer (MBC) has increased in incidence with improved systemic disease control. Current treatment options include radiation therapy (to symptomatic sites) and systemic treatment [intrathecal (IT) or intravenous (IV) chemotherapy]. Methotrexate (MTX), thiotepa and cytarabine are the most commonly used IT agents, while high-dose MTX is the most common IV regimen. While IT treatments are generally well tolerated, complications like chemical meningitis, leukoencephalopathy, etc. occur. LMC may cause a breakdown in the blood–brain barrier and thus allow systemic agents to penetrate; however, efficacy is reported only for agents administered at high doses (MTX). We report our institution’s experience in using IV thiotepa as treatment for LMC secondary to MBC. We conducted a retrospective chart review of 13 patients with MBC who developed LMC and treated with IV thiotepa at our institution. It was administered at 40 mg/m2 every 21 days; median number of thiotepa cycles administered was 5 with the major dose-limiting toxicity being myelosuppression. Four had partial response, 3 had stable disease and 6 had progressive disease. The 6-month survival rate was 69 % and 1-year survival rate was 31 %. Despite retrospective nature of our case series, we found the use of IV thiotepa as sole treatment for LMC in patients with MBC to be well tolerated, easily administered in the ambulatory setting, and with efficacy comparable to the other chemotherapeutic agents commonly used in the treatment of LMC. This regimen warrants further investigation in prospective studies.
References
Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM (2010) Leptomeningeal metastases in the MRI era. Neurology 74(18):1449
Rhun EL, Taillibert S, Chamberlain MC (2013) Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 4:S265–S288
Bokstein F, Lossos A, Siegal T (1998) Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 82(9):1756–1763
Boogerd W, vd Sande JJ, Moffie D (1988). Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrextate. J Neurol Neurosurg Psychiatry 51:277–283
Beauchesne P (2010) Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumors. Lancet Oncol 11:871–879
Comte A, Jdid W, Guilhaume MN et al (2013) Survival of breast camcer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neurooncol 115:445–452
Tetef MI, Margolin KA, Doroshow JH et al (2000) Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46:19–26
Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561–569
Le Rhun E, Taillibert S, Devos P, Zairi F et al (2013) Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases: a retrospective case series. Anticancer Drugs 24:1093–1097
Strong JM, Collins JM, Lester C, Poplack DG (1986) Pharmacokinetics of intraventricular and intravenous N, N′, N″-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 46(12):610–614
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chahal, J., Stopeck, A., Clarke, K. et al. Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series. Neurol Sci 36, 1691–1693 (2015). https://doi.org/10.1007/s10072-015-2259-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-015-2259-1